Search
Secnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigationalIt is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class … [A27210] Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalIt was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … The average age of diagnosis is between age 65 to 74.
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigational[L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] … [A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr.
Ferric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalThe latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … [L11581,L11587] Clinical trials show that it is non-inferior to [iron sucrose], another form of iron that is often administered in iron deficiency, and less likely to cause serious hypersensitivity that
Plasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with
Estradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedHowever, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].
Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawn[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012. … It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).
Ziprasidone
go.drugbank.com/drugs/DB00246ApprovedInvestigationalgenerally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles. … [A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalto its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA. … [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease